Roivant terminates $250M Cantor purchase agreement, appoints new director

Roivant Sciences Ltd.

Terminated $250M Common Shares Purchase Agreement with Cantor effective by Oct 5, 2022; entered new Sales Agreement with Cowen on Sept 19, 2022.
Director Masayo Tada resigned effective Sept 16, 2022; no dispute with company or board.
Board appointed Hiroshi Nomura (President/CEO of Sumitomo Pharma) as Class III director effective Sept 16, 2022; waived compensation.
At Sept 15 AGM, shareholders elected Class I directors Gline, Manchester, Epperly and ratified Ernst & Young as auditor.

item 1.02 item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hiroshi Nomura

Class III director

ROIV · Roivant Sciences Ltd.

Effective: 2022-09-16
Filed: September 21, 2022, 7:59 PM ET

Also on September 15, 2022, the Board appointed Hiroshi Nomura to serve as a Class III director of the Board, effective September 16, 2022, filling the vacancy created by and concurrent with the resignation of Mr. Tada from the Board.

Departed

Masayo Tada

director

ROIV · Roivant Sciences Ltd.

Effective: 2022-09-16
Successor: Hiroshi Nomura
Filed: September 21, 2022, 7:59 PM ET

On September 15, 2022, Masayo Tada resigned as a director of the Company, effective September 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hiroshi Nomura was appointed as Class III director at Roivant Sciences Ltd..

Action: appointed
Role: Class III director

Exact text from the filing

Also on September 15, 2022, the Board appointed Hiroshi Nomura to serve as a Class III director of the Board, effective September 16, 2022, filling the vacancy created by and concurrent with the resignation of Mr. Tada from the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Masayo Tada resigned as director at Roivant Sciences Ltd..

Action: resigned
Role: director

Exact text from the filing

On September 15, 2022, Masayo Tada resigned as a director of the Company, effective September 16, 2022.

View on SEC.gov

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-22-034294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.